Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) specialising in the integrated delivery of in vivo pharmacology, DMPK, toxicology and translational bioanalysis to accelerate the development of innovative therapeutics. Founded in 2002, the company combines deep scientific expertise with operational agility to support biotech, pharma and academic innovators from discovery through IND-enabling studies. Our platform spans multiple therapeutic areas including CNS, oncology, metabolic and respiratory disease, and supports both small molecules and advanced modalities such as biologics, RNA-based therapeutics and gene-directed platforms. We operate GLP-accredited facilities and offer a highly flexible model that enables rapid study design, execution and data interpretation, shortening critical decision cycles and reducing development risk. Pharmidex differentiates through scientific leadership, multidisciplinary integration and close client collaboration, acting as an extension of R&D teams rather than a transactional supplier. Our vision is to enable faster and more cost-effective translation of transformative therapeutic concepts into the clinic, particularly supporting SMEs and early-stage innovators who lack internal development infrastructure. By bridging discovery science with regulatory expectations, we help ensure that promising innovations are clinically and commercially viable, contributing to improved patient outcomes and a more dynamic European biotech ecosystem.